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120 Poster Session-IIMethods: 20 pts with hematological malignancies were given
MSC (1–2  10E6 cells/kg) from third party donors a few hours be-
fore PBSC from HLA-mismatched unrelated donors, after condi-
tioning with 2 Gy TBI and fludarabine 90 mg/m2. Postgrafting
immunosuppression included tacrolimus (day -3 to 1180; tapered
by day 1365) and mycophenolate mofetil (tid days 0 to 142).
HLA-compatibility was assessed at the HLA-A, -B, -C, -DRBI and
DQBI loci. 12 pairs were mismatched for at least one HLA class I an-
tigen (including 4 pairs who were also mismatched for 1 HLA-class
II antigens (n 5 3) or 1 HLA-class I allele (n 5 1)), 1 pair was mis-
matched for 2 HLA class II alleles, and 7 pairs were mismatched
for a single HLA class I (n 5 4) or HLA class II (n 5 3) alleles.
Results: Median follow-up for surviving pts was 219 (range, 13–
519) days, and 17 pts are already evaluable for day 100 nonrelapse mor-
tality (primary endpoint). Thus far, 1 patient with secondary AML had
primary graft rejection, while the remaining pts had sustained engraft-
ment. Median donor T-cell chimerism levels on days 28, 100, 180 and
365 after HCT were 91%, 97%, 96%, and 98%, respectively. Grade
II, III and IV acute GVHD were seen in 4, 2 and 0 pts, respectively.
Two pts died of non-relapse causes on days 74 and 114 after HCT,
while 3 pts died of disease progression. Projected 1-yr overall and pro-
gression-free survivals were 74% and 62%, respectively.
Conclusions: HLA-mismatched nonmyeloablative HCT with
MSC co-infusion appeared to be safe. These encouraging results,
suggesting improved outcomes compared to similar pts not co-
infused with MSC, should be confirmed in a larger multicenter study.
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ANTITHYMOCYTE GLOBULINS (ATG) AS PART OF THE MYELOABLATIVE
CONDITIONING (MAC) REGIMEN CAN REDUCE THE RISK OF SEVERE
GRAFT-VS.-HOST DISEASE (GVHD) AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLO-SCT) FROM MATCHED-UNRELATED DONORS
(MUD) [A SFGM-TC STUDY]
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Here, we report the results of a multicenter retrospective study an-
alyzing the effect of ATG, incorporated within the MAC regimen for
MUD-transplants in leukemic patients. The purpose of the study was
to compare the incidence and severity of acute and chronic GVHD as
well as overall outcome. 171 adult patients with acute leukemia and
MDS, for whom detailed allelic HLA typing (4 digits) was available,
were included. 81% of patients were transplanted from 10/10 allelic
MUD, and 19% from a MUD with at least one allelic difference. 120
patients (70%) did not receive ATG (‘‘no-ATG’’ group), while 51 pa-
tients received ATG (‘‘ATG’’ group; Thymoglobuline*, Genzyme in
all cases) as part of the MAC regimen. Except for a significantly higher
number of allelic differences between recipient and donor (33% vs.
13%; P 5 0.002), the ‘‘no-ATG’’ and ‘‘ATG’’ groups were strictly
comparable. With a median follow-up of 30.3 (range, 2.6–68.1)
months, grade 0–1 and 2–4 acute GVHD occurred in 74 (46%) and
88 patients (54%) respectively, with grade 3–4 acute GVHD being
significantly lower in the ‘‘ATG’’ group (18% vs. 32%; P 5 0.04).
Limited and extensive chronic GVHD were observed in 22 and
25% of assessable patients respectively, with extensive chronic
GVHD being significantly lower in the ‘‘ATG’’ group (5% vs.
33%; P 5 0.001). Interestingly, patients from the ‘‘ATG’’ group
had a higher incidence of limited chronic GVHD (33% vs. 18%;
P5 0.06). Moreover, infection-related mortality was comparable be-
tween both groups (23% vs. 27%, P5NS). Also, NRM was compa-
rable between both groups (30% vs. 29%; P 5NS). In multivariate
analysis, an HLA allelic mismatch and the non-use of ATG were as-
sociated with an increased risk of grade 3–4 acute GVHD (RR52.80,
95%CI, 1.5–5.3, P5 0.001; and RR5 2.4, 95%CI, 1.1–5.0, P5 0.02
respectively). Similarly, multivariate analysis showed that the absence
of use of ATG was the unique parameter associated with an increasedrisk of extensive chronic GVHD (RR 5 6.9; 95%CI, 1.7–29.0, P 5
0.008). Finally, LFS and OS at 2 years were not significantly different
between the ‘‘no-ATG’’ and ‘‘ATG’’ group (48.8% vs. 41.3%, P 5
NS; and 53.6% vs. 54.3%, P5NS; respectively). These results sug-
gest a global long-term beneficial effect of ATG when used as part of
the MAC regimen prior to allo-SCT from MUD (especially in the
HLA mismatch setting). Such protective effect of ATG against severe
GVHD can be likely achieved without an increased risk of infections
or leukemia recurrence.335
HUMAN MEMORY T CELL S ELICIT DECREASED CYTOTOXICITY AGAINST
ALLOGENEIC TARGETS
Zheng, Q., Deoliveira, D., Chao, N.J., Chen, B.J. Duke University Med-
ical Center, Durham, NC
Several groups have independently demonstrated that memory T
cells do not induce graft-versus-host disease in several different ani-
mal models. To test whether the same concept applies to humans, we
compared the ability of memory T cells to respond to alloantigens
with that of naive T cells. Purified T cells were first obtained from
peripheral blood from healthy donors and then separated into mem-
ory and naive T cell subsets based on the expression of CD45RA
(memory: CD45RA-, naive: CD45RA1). Memory T cells were
then tested for their ability to respond to alloantigens by using sev-
eral standard in vitro assays. In contrast to the mouse data, memory
T cells proliferated equally well as naive T cells did in mixed lympho-
cyte culture. Despite the similar proliferative responses against allo-
antigens as those mediated by naive T cells, these same memory T
cells failed to kill the allogeneic targets. Limiting dilution assay dem-
onstrated that the frequency of allospecific cytotoxicity T cells was
6–68.5 fold less in memory T cells than that in naive T cells. Inter-
leukin 2 was unable to restore the cytotoxicity against alloantigens.
The results from skin explant assay further suggested that, in con-
trast to naive T cells, memory T cells might not be able to induce
graft-versus-host disease. These data suggest that human memory
T cells contain less alloantigen-specific cytotoxicity T cells and
may not cause graft-versus-host disease upon in vivo transfer. Since
clinical grade antibody is now available, this approach will soon be
tested in humans for the prevention of graft-versus-host disease.336
PROGNOSTIC FACTORS AND OUTCOMES OF SEVERE GASTROINTESTINAL
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Treatment of severe GI GVHD poses a challenge, as little prog-
ress has been made in developing better treatments, survival remains
poor and it is difficult to know the ultimate severity of GVHD and
the outcome at the onset of symptoms. We reviewed the records of
117 consecutive patients transplanted between 2000–2005 who de-
veloped stages 3–4 GI GVHD. Data were collected for more than
20 parameters including stool volume, abdominal pain, melena, up-
per GI symptoms, serum albumin, number of treatments, visual find-
ings at endoscopy and histopathologic grade of GI biopsies. Clinical
parameters were measured as the peak value during each 14 day pe-
riod starting from 2 weeks before the diagnosis of GI GVHD to the
resolution of symptoms, loss of follow-up or patient death. Median
onset of symptoms was day 29 (range 4 – 135); 11 (9.6%) patients
presented after day 80. Mean daily stool volume at diagnosis was
1831.12 61438.16mL/day. At onset of GI symptoms, 56% of pa-
tients had $ stage 1 skin GVHD and 62% had $ stage 1 liver
GVHD. At onset, 78% had upper GI symptoms and 55% of patients
presented with severe abdominal pain. Within the first 2 weeks after
the diagnosis of GI GVHD, 62 (53%), 37 (31.6%), 4 (3.4%), 13
(11.2%) and 1 (0.8%) patients had a peak GI stage of 4, 3, 2, 1 and
0 respectively. All patients received high dose prednisone/predniso-
lone as initial treatment; 67 received 2nd line therapy; and 32 received
three or more lines of treatment. Non-relapse mortality was 71%
and 41% at 1 year after transplant in patients with steroid-refractory
and steroid-responsive GVHD, respectively. Overall survival was
